HPV infection is on the rise in teens and typically transient—yet it still raises the risk of dysplasia. The authors offer evidence-based yet practical guidelines for this management challenge.
The role of HPV
When to screen?
The goal of cervical cancer screening is to identify significant preinvasive lesions and prevent development of invasive cervical cancer. Age 18 has traditionally been accepted as the time to start cytologic screening, but recent consensus panels have recommended initiating screening later. The benchmark now is 3 years after the onset of sexual activity, but not later than age 21.12-14 This recommendation is based on the natural history of HPV infection and the rarity of cervical cancer in adolescents. The incidence of cervical cancer is 0 per 100,000 per year in girls aged 10 to 14 and 1.7 per 100,000 for those aged 15 to 19, according to the Surveillance, Epidemiology, and End Results database.15 Earlier screening is unlikely to add additional benefit and may lead to overtreatment of lesions that would spontaneously regress.
Link between prenatal air pollution and reduced lung function in offspring reported
July 25th 2024Higher prenatal exposure to PM2.5 pollution is associated with reduced lung volume and airflow limitation in children, highlighting the critical impact of air pollution on in utero lung development.
Read More
Cut costs observed from out-of-home care in children with prenatal substance exposure
July 24th 2024A recent study reveals that while children exposed to maternal substance use face higher hospital costs up to age 20 years, out-of-home care significantly mitigates this financial burden.
Read More
Global progress in neonatal tetanus elimination from 2000 to 2022
July 18th 2024Incorporating maternal and neonatal tetanus elimination strategies into national immunization activities is crucial for sustaining elimination and reducing neonatal mortality worldwide, as highlighted by the latest CDC report.
Read More
PreTRM test shows efficacy in reducing severe neonatal morbidity and mortality
July 18th 2024The PreTRM test, a blood-based biomarker test for predicting preterm birth risk, has demonstrated significant efficacy in lowering severe neonatal morbidity and mortality, as reported by Sera Prognostics Inc.
Read More